Cardiovascular effect of [3,4-dihydro-8-(2-hydroxy-3-isopropylaminopropoxy)-3-nitrato-2H-1-benzopyran] (K 351).
Cardiovascular effect of a new compound, K 351, was examined in anesthetized dogs. Intravenous injections of 100 micrograms/Kg or over of K 351 caused a fall in systemic blood pressure, reduced peripheral vascular resistance, left ventricular enddiastolic pressure, max dP/dt and Vmax, and increased time constant T and PQ interval. Heart rate was reduced with 1 microgram/Kg K 351. The magnitudes of the changes in heart rate, T and PQ interval were not different between K 351 and propranolol groups, while those in max dP/dt and Vmax caused by K 351 were larger than those induced by the same doses of propranolol. It is suggested that K 351 suppressed left ventricular contractility, sinus node activity and atrioventricular conduction through its beta-receptor blocking action and reduced peripheral vascular resistance and left ventricular enddiastolic pressure through its vasodilating action.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects*; D009200:Myocardial Contraction / Q000187:drug effects; D011412:Propanolamines / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology; D014655:Vascular Resistance / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D011433:Propranolol; C036089:nipradilol